Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Year: 2024
Type: conference-abstract
Source: Blood
Institutions: Hôpital Lyon Sud, Genentech, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, National Taiwan University Hospital, Washington University in St. Louis, Roche (Switzerland), IRCCS Humanitas Research Hospital
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405042535